NATIONAL DIABETIC SCREENING PROGRAMME
Kowa Optimed has announced that its latest innovation, the Nonmyd WX 3D, has been approved for the English National Screening Programme for Diabetic Retinopathy in the UK. With over five million people expected to have diabetes in the UK by 2025, and with diabetic retinopathy being the main cause of blindness in the 16-65 year-old age group, the National Screening Programme aims to reduce the risk of sight loss by offering annual screening to diabetic patients for prompt identification and effective treatment of sight-threatening retinopathies.
www.kowa.eu/medicals
Latest Articles
Beyond the Numbers
Empowering patient participation fosters continuous innovation in cataract surgery.
Thinking Beyond the Surgery Room
Practice management workshop focuses on financial operations and AI business applications.
Aid Cuts Threaten Global Eye Care Progress
USAID closure leads retreat in development assistance.
Supplement: ESCRS Clinical Trends Series: Presbyopia
Debate: FS-LASIK or KLEx for Hyperopia?
FS-LASIK has more of a track record, but KLEx offers advantages.
Four AI Applications Ready for Practice
Commercial offerings may save time, improve practice and research.
Perioperative Medication Regimens for Cataract Surgery
Randomised controlled clinical trial results provide evidence-based guidance.
Should Fuchs’ Dystrophy Patients Get Premium Lenses?
Patients’ demand for premium IOLs despite contraindications pose a challenge in Fuchs’ dystrophy treatment.
Avoiding Posterior Capsule Rupture
Imaging may help, but surgical technique is key for managing posterior polar cataracts.